These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 21710313)
1. Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures. Ettner SL; Steers WN; Turk N; Quiter ES; Mangione CM J Gen Intern Med; 2011 Oct; 26(10):1195-200. PubMed ID: 21710313 [TBL] [Abstract][Full Text] [Related]
2. Entering and exiting the Medicare part D coverage gap: role of comorbidities and demographics. Ettner SL; Steers N; Duru OK; Turk N; Quiter E; Schmittdiel J; Mangione CM J Gen Intern Med; 2010 Jun; 25(6):568-74. PubMed ID: 20217267 [TBL] [Abstract][Full Text] [Related]
3. The effect of Medicare Part D on drug and medical spending. Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283 [TBL] [Abstract][Full Text] [Related]
4. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase. Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080 [TBL] [Abstract][Full Text] [Related]
5. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D. Blumberg DM; Prager AJ; Liebmann JM JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853 [TBL] [Abstract][Full Text] [Related]
6. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study. Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193 [TBL] [Abstract][Full Text] [Related]
7. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. Polinski JM; Shrank WH; Huskamp HA; Glynn RJ; Liberman JN; Schneeweiss S PLoS Med; 2011 Aug; 8(8):e1001075. PubMed ID: 21857811 [TBL] [Abstract][Full Text] [Related]
8. The impact of the Medicare Part D prescription benefit on generic drug use. Zhang JX; Yin W; Sun SX; Alexander GC J Gen Intern Med; 2008 Oct; 23(10):1673-8. PubMed ID: 18661190 [TBL] [Abstract][Full Text] [Related]
9. The impact of Medicare prescription drug coverage on the use of antidementia drugs. Fowler NR; Chen YF; Thurton CA; Men A; Rodriguez EG; Donohue JM BMC Geriatr; 2013 Apr; 13():37. PubMed ID: 23621892 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance. DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016 [TBL] [Abstract][Full Text] [Related]
11. Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis. Hohmann N; Hansen R; Garza KB; Harris I; Kiptanui Z; Qian J Value Health; 2018 Oct; 21(10):1186-1191. PubMed ID: 30314619 [TBL] [Abstract][Full Text] [Related]
12. Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance program. Bishop CE; Ryan AM; Gilden DM; Kubisiak J; Thomas CP Health Serv Res; 2009 Jun; 44(3):1010-28. PubMed ID: 19291168 [TBL] [Abstract][Full Text] [Related]
14. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Yin W; Basu A; Zhang JX; Rabbani A; Meltzer DO; Alexander GC Ann Intern Med; 2008 Feb; 148(3):169-77. PubMed ID: 18180465 [TBL] [Abstract][Full Text] [Related]
15. Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D. Madden JM; Adams AS; LeCates RF; Ross-Degnan D; Zhang F; Huskamp HA; Gilden DM; Soumerai SB JAMA Psychiatry; 2015 Feb; 72(2):179-88. PubMed ID: 25588123 [TBL] [Abstract][Full Text] [Related]
16. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis. Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722 [TBL] [Abstract][Full Text] [Related]
17. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Fung V; Mangione CM; Huang J; Turk N; Quiter ES; Schmittdiel JA; Hsu J Health Serv Res; 2010 Apr; 45(2):355-75. PubMed ID: 20050931 [TBL] [Abstract][Full Text] [Related]
18. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017. Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594 [TBL] [Abstract][Full Text] [Related]
19. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more? Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108 [TBL] [Abstract][Full Text] [Related]
20. Impact of cost sharing on prescription drugs used by Medicare beneficiaries. Goedken AM; Urmie JM; Farris KB; Doucette WR Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]